Druckenmiller’s Big Bet on Natera | Business and Finance News

Billionaire investor Stanley Druckenmiller has made Natera his top holding, pouring nearly $613 million into the genetic testing giant—making up 18% of his portfolio as of Q1 2026. While not flashy like Nvidia, Natera is riding a booming market projected to grow from $11.7B to nearly $40B by 2030. Focused on cell-free DNA for cancer, organ, and women’s health, the company saw 800K oncology tests last year—with numbers climbing—and just got Japanese approval for its Signatera test. Revenue jumped 36% to $2.3B last year, and they’ve already hit 1M tests in a single quarter this year. Analysts mostly recommend a buy, but Natera’s still burning cash in R&D, making this a high-reward, high-risk bet. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c507a6b488b17283